An interventional study of ABLE Daily in Spinal Cord Injury, sponsored by ABLE Human Motion S.L.. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by ABLE Human Motion S.L. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Spinal Cord Injuries with a site in Netherlands — 5 open to participants now, 6 under way, none of them phase 3. Spinal Cord Injuries · Netherlands.
Among the 22 studies in Spinal Cord Injuries with a site in Netherlands, this one is the 12th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 17 with no phase, and was the 20th registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →5 of the 22 studies in Spinal Cord Injuries with a site in Netherlands are open now. Recruiting first, the newest first:
UMC Utrecht · Sites in Netherlands
Ages 18–70
Annemie Spooren · Sites in Netherlands, Belgium
Ages 16–90
ONWARD Medical, Inc. · Sites in Netherlands
Ages 18+
Stichting Reade · Sites in Netherlands
Ages 17–85
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 10 is below the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 18 across the 18 interventional studies, 33 across the 4 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 22 have an industry lead sponsor. The 10 most frequent:
ABLE Human Motion S.L. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
ABLE Human Motion S.L. has 8 studies filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
3 of the studies in Spinal Cord Injuries with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06065384Annemie SpoorenNeural Plasticity and Motor Recovery After Upper Extremity Motor Training in People With c-SCI | 2027-03-28 |
| NCT07645144Stichting ReadeFES-assisted Gait Training for Incomplete Spinal Cord Injury | 2027-04-01 |
| NCT07640711UMC UtrechtInnovative Brain-Computer Interface for People With Spinal Cord Injury | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Spinal Cord Injuries with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to to confirm the safety and performance of the ABLE Daily to perform ambulatory functions in home and community settings for people with spinal cord injury.
The experimental period will cover the training period with the ABLE Daily exoskeleton (3 weeks of use at the investigational site with a total of 9 sessions) and the home period (12 weeks of personal use at home and community environments).
The ABLE Daily Exoskeleton is a wearable powered lower-limb exoskeleton that actively assists individuals with spinal cord injury to stand up, walk, ascend and descend a ramp of 5 degrees and sit down. The device consists of a rigid brace that attaches to the torso, legs and feet of the user via straps and supports. It is a bilateral robotic exoskeleton with four battery-powered motors that drive the knee and hip joints assisting in flexion-extension. The other degrees of freedom of the hip and knee joints are restricted. The ankle joint of the exoskeleton is passively articulated with a spring within a limited range of motion.
The experimental period will cover the training period happening at the investigational site where the participants and their companions will be trained 3 times a week. They will then have to perform a community skills test, if passed they will be allowed to take the exoskeleton home and use it in their daily life for 12 weeks. Pre and post assessments will be made.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participants will receive training sessions with the ABLE Daily at Sint Maartenskliniek. After they pass the skills and knowledge exam, they will receive the ABLE Daily at their disposal at home for twelve weeks.
Device: ABLE Daily
The participants will receive training sessions with the ABLE Daily at Sint Maartenskliniek. After they pass the skills and knowledge exam, they will receive the ABLE Daily at their disposal at home for twelve weeks
Safety of the device
The total number of adverse events and serious adverse events related to the investigational device at the end of the study will be measured.
Time frame: Through study completion (up to 16 weeks)
Performance of the device during the training period
The number and type of device errors or use errors during the training period.
Time frame: Through the training period (up to 3 weeks) from training session 1-9
Performance of the device in the home/community period
The amount of use of the device during the home/community use period, as measured by the number of sessions and the walking time, number of steps, and distance walked per session.
Time frame: Through the home/community period (up to 12 weeks)
Performance of the device in the home/community period
The usability of the device as measured by the purpose and location of use of the device during the home/community use period which will be registered in a logbook by the participant.
Time frame: Through the home/community period (up to 12 weeks)
Performance of the device in the home/community period
The number and type of device errors at the end of the home/community use period will be registered.
Time frame: Through the home/community period (up to 12 weeks)
Perceived health status
The change from baseline to final assessment of the overall perceived health status of the participants, as measured by the scores of the 36-Item Short Form Survey Instrument (SF-36). Scores for the different domains are converted and pooled using a scoring key, for a total score indicating a range of low to high Quality of Life. Lower scores indicate more disability, while higher scores indicate less disability.
Time frame: At baseline and the final assessment at end of the study (16 weeks)
Gait performance while using the device (6MWT)
The change from the Community Skills Test to the final exoskeleton assessment of the 6-Minute Walk Test (6MWT). The outcome will be the distance walked during the 6 minutes after the training period and once again after the home period.
Time frame: After training period (3 weeks) and at the final assessment at the end of the study (16 weeks)
User satisfaction
The general user satisfaction of participants, companions, and therapists at the end of the study, as measured by the scores of the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0). 12 item instrument used to assess satisfaction with a specific assistive device; eight of these items assess characteristics of that assistive device and the remaining four items assess service and include: 1. Service delivery 2. Repairs and service of the device 3. Professionalism of service 4. Follow-up service Participants are asked to rate their satisfaction for the device on a five point scale that ranges from "not satisfied" at all to "very satisfied." Finally, participants are asked to choose the three most important items related to the assistive device in question System Usability Scale (SUS) to measure the perceived usability of the device. The scales value from 0 to 4 (with four being the most positive response).
Time frame: At the final assessment at the end of the study (16 weeks)
Gait performance using the device: 10-Meter Walk Test (10MWT)
The 10 meter walk test will be used to compare performance after the training period and once again after the home period to monitor any changes in speed.
Time frame: After training period (3 weeks) and at the final assessment at the end of the study (16 weeks)
Cardiovascular health
Blood draw test to check levels of high-density lipoprotein cholesterol (HDL-c), Low-Density Lipoprotein Cholesterol (LDL-c), Triglyceride (TG), and Total Cholesterol (TC). Improvement is indicated with lower values of LDL-c and lower Triglycerides
Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)
Respiratory Parameters
Spirometry to assess the force vital capacity (FVC). FVC is crucial for evaluating lung function and respiratory and global health. Improvement indicates higher values of FVC.
Time frame: Baseline assessment, during the 6 minute walk test and at the final assessment at the end of the study (16 weeks)
Spasticity
Visual analog scale (VAS) is a self-report tool that allows individuals to rate their perceived level of spasticity on a continuous scale, typically ranging from 0 to 10, where higher scores indicate greater severity. Spasticity is a complex phenomenon that can vary greatly in intensity and impact from person to person. The VAS provides a means for individuals to subjectively quantify and communicate their experience of spasticity, capturing nuances that may not be fully captured by objective measures alone. 0 indicated no spasticity and 10 indicates the most spasticity experienced.
Time frame: Baseline assessment, end of training period (3 weeks), final assessment at the end of the study (16 weeks)
Bowel and bladder management (SCI-QOL)
Bladder Management Difficulties and Bowel Management Difficulties items from the Spinal Cord Injury - Quality of Life (SCI-QOL) questionnaire. The SCI-QOL questionnaire is a validated measure specifically designed to assess the quality of life in individuals with SCI across various domains, including bladder and bowel function
Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)
Body composition using BMI
Body weight provides valuable information about body composition. Body Mass Index (BMI) is a simple and straightforward measure calculated using an individual's weight and height. BMI provides a numerical value that categorizes individuals into different weight status categories, such as underweight, normal weight, overweight, or obese.
Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)
Insulin Sensitivity
Blood draw test to obtain the homeostatic model assessment (HOMA-IR), an indirect method to quantify insulin resistance and pancreatic β-cell function. HOMA-IR is a mathematical model used to estimate insulin resistance based on fasting glucose and insulin levels. Higher values indicate higher insulin resistance therefore an improvement would be a lower value.
Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)
Sleep
The 8-item PROMIS (Patient-Reported Outcomes Measurement Information System) Sleep-Related Impairment questionnaire to measure alertness, sleepiness, tiredness, and functional impairments associated with sleep problems during waking hours. It assesses sleep disturbance over the past seven days. PROMIS instruments are scored using item-level calibrations on a 5 point likert scale from not at all to very much. Higher T-scores indicate greater sleep disturbance.
Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)
Body Composition: Waist circumference
Waist circumference measures the circumference of the waist at a specific point, typically at the level of the natural waist or the midpoint between the lower rib and the iliac crest. Lower values indicate better health.
Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)
Respiratory Parameters
Spirometry to assess the forced expiratory volume in 1 second (FEV1). FEV1 is crucial for evaluating lung function and respiratory and global health. A higher value indicates better respiratory function
Time frame: Baseline assessment, during the 6 minute walk test and at the final assessment at the end of the study (16 weeks)
Respiratory Parameters
Spirometry to assess the forced expiratory flow (FEF). FEF is crucial for evaluating lung function and respiratory and global health. A higher value indicates better respiratory function.
Time frame: Baseline assessment, during the 6 minute walk test and at the final assessment at the end of the study (16 weeks)
Respiratory Parameters
Spirometry to assess the peak expiratory flow (PEF). PEF is crucial for evaluating lung function and respiratory and global health. A higher value
Time frame: Baseline assessment, during the 6 minute walk test and at the final assessment at the end of the study (16 weeks)
Respiratory Parameters
Spirometry to assess the maximal voluntary ventilation (MVV). MVV is crucial for evaluating lung function and respiratory and global health. A higher value would indicate better lung function.
Time frame: Baseline assessment, during the 6 minute walk test and at the final assessment at the end of the study (16 weeks)
Bowel and bladder management (BSS)
The Bristol Stool Scale categorizes stool consistency into seven distinct types, ranging from hard lumps (Type 1) to watery diarrhea (Type 7), based on visual descriptions and illustrations. The BSS provides a standardized and objective method for individuals to describe their stool consistency, facilitating communication with healthcare providers.
Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.
Of 49 industry-sponsored interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 16 months is close to that.
Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ABLE Human Motion S.L.